Clinical Trial Update: Predicting Inflammatory Skin Disease Response to IL-23 Blockade [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial from UC San Francisco evaluated whether biomarkers can predict response to IL-23 blockade in psoriasis vulgaris, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Snippet

Sponsor: University of California, San Francisco | Conditions: Psoriasis Vulgaris | Phase 4 | Status: COMPLETED | Results posted: 2024-04-30